Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denardo

Showing results (31-40 of 662) with videos related to

Pageof 67
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Radiolabeled anti-lymphoma antibodiesG L DeNardo, R T O'Donnell, S J DeNardo
Cancer|December 24, 1997
Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignanciesS Shen, G L DeNardo, R T O'Donnell, et al.
Seminars in Oncology|March 24, 2005
Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspectiveGerald L DeNardo
Seminars in Nuclear Medicine|March 15, 2005
Radioimmunodetection and therapy of breast cancerSally J DeNardo
Hybridoma|April 22, 1999
Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RITS J DeNardo, G L DeNardo, J Brush, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 7, 2003
Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapyChristine L Hartmann Siantar, Gerald L DeNardo, Sally J DeNardo
Cancer Biotherapy & Radiopharmaceuticals|January 10, 2006
Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograftLaird Miers, Sally J DeNardo, Kathleen Lamborn, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2002
Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategyGerald L DeNardo, Christine L Hartmann Siantar, Sally J DeNardo
Seminars in Nuclear Medicine|August 16, 2005
Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs)Gerald L DeNardo
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1999
67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphomaG L DeNardo, D L Kukis, S Shen, et al.
Pageof 67

Showing results (31-40 of 662) with videos related to

Sort By:
Pageof 67
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Radiolabeled anti-lymphoma antibodiesG L DeNardo, R T O'Donnell, S J DeNardo
Cancer|December 24, 1997
Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignanciesS Shen, G L DeNardo, R T O'Donnell, et al.
Seminars in Oncology|March 24, 2005
Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspectiveGerald L DeNardo
Seminars in Nuclear Medicine|March 15, 2005
Radioimmunodetection and therapy of breast cancerSally J DeNardo
Hybridoma|April 22, 1999
Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RITS J DeNardo, G L DeNardo, J Brush, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 7, 2003
Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapyChristine L Hartmann Siantar, Gerald L DeNardo, Sally J DeNardo
Cancer Biotherapy & Radiopharmaceuticals|January 10, 2006
Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograftLaird Miers, Sally J DeNardo, Kathleen Lamborn, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2002
Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategyGerald L DeNardo, Christine L Hartmann Siantar, Sally J DeNardo
Seminars in Nuclear Medicine|August 16, 2005
Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs)Gerald L DeNardo
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1999
67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphomaG L DeNardo, D L Kukis, S Shen, et al.
Pageof 67